Here's how Bristol Myers' CEO Giovanni Caforio completed a $13B buyout: He moved fast, upped the bid quickly and demanded everyone to keep up
Bristol Myers Squibb CEO Giovanni Caforio does not waste time. He also likes everyone around him to keep up.
Anyone reading over the insider account filed with the SEC of the back-and-forth over his $13 billion buyout of MyoKardia $MYOK could reach only one conclusion: The CEO who had willingly crafted a $74 billion Celgene acquisition had found something else he liked — and he was willing to pay a nice premium to get it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.